Loading financial data...

Ultragenyx Pharmaceutical Inc. (RARE) Financial Statements | Global Financial Data

Ultragenyx Pharmaceutical Inc.

RARESEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1515673

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$434.0M	$363.3M	$351.4M	$271.0M	$103.7M
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$648.0M	$705.8M	$497.2M	$412.1M	$357.4M
Selling, General and Administrative Expense	$310.0M	$278.1M	$220.0M	$182.9M	$161.5M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$569.0M	-$648.9M	-$381.7M	-$330.1M	-$424.2M
Nonoperating Income (Expense)	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.5B	$1.5B	$1.5B	$1.5B	$1.8B
Assets, Current	$817.0M	$732.2M	$883.9M	$856.6M	$1.3B
Cash and Cash Equivalents, at Carrying Value	$214.0M	$132.9M	$307.6M	$713.5M	$433.6M
Accounts Receivable, after Allowance for Credit Loss, Current	$122.0M	$73.4M	$40.4M	$28.4M	$23.1M
Inventory, Net	$45.0M	$34.0M	$26.8M	$16.2M	$13.0M
Liabilities	$1.2B	$1.2B	$1.2B	$599.8M	$605.2M
Liabilities, Current	$344.0M	$280.4M	$261.2M	$181.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$475.0M	-$380.5M	-$338.7M	-$132.2M	-$345.4M
Net Cash Provided by (Used in) Investing Activities	$168.0M	-$291.7M	-$195.4M	-$179.1M	-$13.0M
Net Cash Provided by (Used in) Financing Activities	$388.0M	$501.2M	$118.6M	$600.3M	$679.3M
Payments to Acquire Property, Plant, and Equipment	$44.0M	$116.1M	$73.1M	$43.9M	$24.8M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)